Grifols Gets $6B Takeover Offer from Founding Family, Brookfield to Go Private
2024-07-08
Pictured: Grifols sign on lawn in front of building in Frankfurt, Germany/iStock, Victor Golmer
Grifols said on Monday it is considering a buy offer from the Catalan family and Canadian investment firm Brookfield which would delist it from the Spanish and Nasdaq stock markets, according to multiple media outlets. The deal is potentially worth around $6 billion based on the current market value.
“According to the information provided to the Board of Directors, Brookfield and the Family Shareholders have reached an agreement to evaluate a possible joint takeover bid to acquire all the share capital of Grifols,” the company said, according to a statement provided by Spain’s regulator.
The Catalan family currently controls around 30% of the company's shares. Trading of Grifols’ stock was suspended early Monday morning by the Spanish regulator, Comision Nacional del Mercado de Valores, but has since resumed trading. The stock is trading over 30% higher in premarket on takeover interest.
The founding family of GrifolsGrifols is looking to take back control of the plasma-based medicines manufacturer following a tumultuous year. A short-seller attack in January 2024 sent the company’s shares tumbling and wiped $3.83 billion from Grifols’ valuation at the time, after Gotham City Research questioned the manufacturer’s accounting practices and alleged that Grifols is overstating earnings and understating debt.
In response to the allegations, Grifols denied any wrongdoing but removed all family members from executive positions and hired an outside CEO and CFO.
Barclays analyst Charles Pitman said Monday that the potential takeover would allow a new management team to focus on improving operations. GrifolsGrifols is currently saddled with over $10.8 billion in debt, according to CincoDías news, with more than $3.1 billion maturing this year and $3.3 billion in 2027.
On the positive side of the ledger, GrifolsGrifols scored a recent win with the FDA approval last month of Yimmugo, an intravenous immunoglobulin treatment for primary immunodeficiencies. The asset was picked up in a 2022 acquisition of Biotest. Grifols expects Yimmugo to reach $1 billion in sales over the next seven years.
Kate Goodwin is a freelance life science writer based in Des Moines, Iowa. She can be reached at kate.goodwin@biospace.com and on LinkedIn.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。